Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Last trade$29.16
Day change+$0.07 (+0.24%)
Day range$28.81 – $29.69
Volume225,841
Market cap$1.09B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.09B
Price / earnings
—
Price / book
37.41×
Price / sales
3.6×
EV / sales
4.32×
EV / EBITDA
80.11×
Profitability
Earnings per share
-$0.76
Return on assets
-6.43%
Return on equity
-97.6%
Dividend yield
0%
Liquidity and leverage
Debt / equity
10.03×
Current ratio
2.29×
Quick ratio
2.12×
Cash ratio
0.66×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$20.35M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HROW, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$99.3M
$70.66M
$44.2M
$89.09M
$71.64M
$63.74M
$47.83M
$66.83M
Cost of revenue
$24.39M
$20.3M
$17.16M
$18.47M
$17.71M
$16.23M
$15.52M
$14.14M
Gross profit
$74.9M
$50.36M
$27.05M
$70.62M
$53.93M
$47.51M
$32.31M
$52.7M
Selling, general and administrative
$53.15M
$53.3M
$43.23M
$43.31M
$35.86M
$33.24M
$40.51M
$34.79M
Research and development
$10.29M
$8.07M
$5.9M
$11.72M
$3.32M
$2.87M
$3.03M
$4.76M
Total operating expenses
$63.43M
$61.37M
$49.13M
$55.03M
$39.18M
$36.1M
$43.54M
$39.8M
Operating income
$11.47M
-$11.01M
-$22.08M
$15.59M
$14.75M
$11.41M
-$11.23M
$12.9M
Interest expense
-$6.21M
-$6.26M
-$5.5M
-$5.19M
-$6.04M
-$6.41M
-$6.55M
-$6.38M
Income before taxes
$10.26M
-$17.27M
-$27.58M
$10.4M
$1.02M
$5M
-$17.78M
$6.26M
Income taxes
$506K
$0
$25K
$3.77M
$0
$0
$0
-$514K
Net income
$9.76M
-$17.27M
-$27.6M
$6.63M
$1.02M
$5M
-$17.78M
$6.78M
Net income attributable to common shareholders
$9.76M
-$17.27M
-$27.6M
$6.63M
$1.02M
$5M
-$17.78M
$6.78M
EBITDA
$17.49M
-$5.02M
-$16.5M
$20.37M
$19.46M
$16.13M
-$6.54M
$17.7M
Basic earnings per share
$0.26
-$0.46
-$0.74
$0.18
$0.03
$0.14
-$0.50
$0.19
Diluted earnings per share
$0.25
-$0.46
-$0.74
$0.20
$0.03
$0.13
-$0.50
$0.19
Recent news
Company coverage with links to the original publishers.
Harrow (HROW) reported Q3 2026 revenue of $99.3 million, up 38.6% year-over-year and slightly beating the consensus estimate of $98.44 million. However, EPS came in at $0.12, missing the consensus estimate of $0.13. The stock has underperformed the broader market, declining 8.4% over the past month, and carries a Zacks Rank #5 (Strong Sell) rating.
Harrow (HROW) reported Q3 2026 earnings of $0.12 per share, missing the consensus estimate of $0.13 and falling short of prior year's $0.33. The pharmaceutical company posted revenues of $99.3 million, slightly beating expectations. However, the stock has declined 45.1% year-to-date and received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions, suggesting continued underperformance ahead.
Profound Medical reported a quarterly loss of $0.21 per share, missing the consensus estimate of $0.19 loss, with an earnings surprise of -10.53%. Revenue of $9.83 million slightly exceeded expectations by 0.31%, but the company has underperformed the S&P 500 by 21.3% year-to-date. Despite the miss, the stock maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.
Prelude Therapeutics (PRLD) is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +9.72% and Zacks Rank #2. The company is projected to report a quarterly loss of $0.14 per share (improved 46.2% year-over-year) on revenues of $5 million (down 23.1%). With a strong history of beating consensus estimates in the last four quarters, PRLD appears positioned for an earnings beat.
Harrow (HROW) is expected to report Q3 2026 earnings on November 9 with a consensus EPS estimate of $0.17 (down 48.5% YoY) but revenues of $99.88M (up 39.4% YoY). With a +44.00% Earnings ESP and Zacks Rank #3, analysts predict the company will likely beat consensus estimates. Pacira BioSciences (PCRX) is also expected to beat estimates with a +0.87% Earnings ESP and Zacks Rank #3.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.